Australia’s trusted immunisation experts
02 November 2022 | NewsAt least two thirds of Australians, including children and adolescents, have had COVID-19, two national antibody studies findRead the full article
Post-licensure surveillance of adverse events following immunisation (AEFI) is an important component of any national immunisation program and essential to maintaining the confidence of the general public and immunisation providers in the national immunisation program.
NCIRS plays a pivotal and collaborative role in monitoring and promoting vaccine safety. A key partner is the Therapeutic Goods Administration (TGA), which monitors AEFI through national passive surveillance and sends AEFI reports data related to vaccines from the Adverse Events Management System (AEMS) in a de-identified form to NCIRS to conduct various analyses. We analyse TGA AEMS vaccine data to prepare regular national AEFI surveillance reports (published annually in the journal Communicable Diseases Intelligence), national immunisation program evaluations, reports to the Australian Technical Advisory Group on Immunisation (ATAGI) and other ad hoc analyses. Find out more here.
NCIRS also leads the following initiatives for a range of important vaccine safety activities:
Paediatric Active Enhanced Disease Surveillance (PAEDS)
NSW Immunisation Specialist Service (NSWISS)
NCIRS's vaccine safety fact sheets provide information on specific issues. These fact sheets have been developed primarily for immunisation providers, but may also be of interest to members of the public.